BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Issues Quarterly Earnings Results

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released its quarterly earnings data on Tuesday. The company reported ($526.11) earnings per share (EPS) for the quarter, FiscalAI reports.

BridgeBio Oncology Therapeutics Price Performance

NASDAQ:BBOT traded up $0.24 during midday trading on Tuesday, hitting $8.13. 223,805 shares of the company traded hands, compared to its average volume of 328,957. The firm has a fifty day moving average price of $9.01. BridgeBio Oncology Therapeutics has a 12-month low of $7.60 and a 12-month high of $14.87. The stock has a market cap of $651.32 million, a price-to-earnings ratio of -5.35 and a beta of 0.22.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BBOT. HC Wainwright boosted their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Canaccord Genuity Group initiated coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday. They set a “buy” rating and a $23.00 price objective for the company. Weiss Ratings initiated coverage on shares of BridgeBio Oncology Therapeutics in a research note on Wednesday, January 14th. They issued a “sell (d+)” rating for the company. Finally, Stifel Nicolaus began coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a “buy” rating and a $23.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BridgeBio Oncology Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BBOT. CIBC Private Wealth Group LLC purchased a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth about $63,000. XTX Topco Ltd raised its position in BridgeBio Oncology Therapeutics by 22.4% in the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock worth $358,000 after purchasing an additional 5,249 shares during the period. Persistent Asset Partners Ltd bought a new stake in BridgeBio Oncology Therapeutics in the fourth quarter worth about $107,000. Squarepoint Ops LLC bought a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $144,000. Finally, Quadrature Capital Ltd bought a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $162,000. Institutional investors own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.